Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12
Capricor Therapeutics (NASDAQ: CAPR) will release its Q2 2021 financial results on August 12, 2021, after market close. Following this, a webcast and conference call will occur at 4:30 p.m. ET to discuss the results and provide a corporate update. Capricor focuses on developing cell and exosome-based therapeutics for various diseases, including Duchenne muscular dystrophy and COVID-19 related conditions. The lead candidate, CAP-1002, is currently in clinical development.
- Upcoming release of Q2 financial results may provide insights into future growth.
- Continuous development of innovative therapies, including CAP-1002 for Duchenne muscular dystrophy and COVID-19.
- None.
Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET
LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the second quarter ended June 30, 2021, after the market close on Thursday August 12, 2021. Management will then host a webcast and conference call at 4:30 p.m. ET on August 12.
| Title: | Capricor Therapeutics Second Quarter 2021 Financial Results and Recent Corporate Update Conference Call and Webcast |
| Date: | Thursday, August 12, 2021 |
| Time: | 4:30 p.m. ET |
| Conference Call Details: | Toll-Free: 866-269-4264 International: 929-477-0577 Conference ID: 1169561 |
| Webcast: | http://public.viavid.com/index.php?id=146080 |
A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on developing transformative cell- and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company’s current focus is on developing exosomes loaded with nucleic acids, including mRNA, to treat or prevent a variety of diseases. For more information, visit www.capricor.com, and follow the Company on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on March 15, 2021 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on May 14, 2021. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 212.896.1204
Investor Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
617.435.6602
Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
310.358.3200
FAQ
When will Capricor Therapeutics release its Q2 2021 financial results?
What time is the Capricor Therapeutics conference call on August 12, 2021?
What is the focus of Capricor Therapeutics?
What is CAP-1002?
